GH Research PLC GHRS
Set alert
As of Nov 2, 3:04 PM ET
- YTD
- +62.13%
- 1 year
- +43.78%
- Open
- 20.91
- Prev close
- 20.86
- Mkt cap
- 1.41B
- Vol
- 322.83K
- Avg vol
- 298.04K
- EPS
- -0.99
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.96
- High
- 21.28
- Forward P/E
- -11.28
- Beta
- 1.32
- Short ratio
- 6.36
- Inst. own
- 72.15%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 24.21
- 200-d avg
- 21.53
- 1y target
- 42.89
News
1 week ago seekingalpha.com
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program
GH Research remains significantly undervalued due to the large unmet need in treatment-resistant depression and GH001's potential efficacy. While early data appears promising, and Eli Lilly's…
1 month ago defenseworld.net
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of GH Research PLC (NASDAQ: GHRS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, MarketBeat…
1 month ago seekingalpha.com
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
I initiate coverage on GH Research PLC with a "Buy" rating, driven by renewed momentum in its GH001 program for treatment-resistant depression [TRD]. The company resolved the FDA clinical hold on its…
-
2 months ago benzinga.com
Guggenheim Maintains Buy on GH Research, Raises Price Target to $40
Guggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $34 to $40.
-
2 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40
Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $35 to $40.
-
2 months ago benzinga.com
Needham Maintains Buy on GH Research, Raises Price Target to $39
Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $32 to $39.
-
2 months ago benzinga.com
GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 53.33 percent decrease over losses of $(0.15)…
2 months ago globenewswire.com
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
Alignment with FDA on CMC and device plans for Phase 3 Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estate Phase 2a…
-
3 months ago benzinga.com
Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44
Wells Fargo analyst Benjamin Burnett initiates coverage on GH Research (NASDAQ:GHRS) with a Overweight rating and announces Price Target of $44.
3 months ago benzinga.com
Why Is GH Research Stock Trading Higher on Thursday?
GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher in response to Eli Lilly and Co. (NYSE:LLY) agreeing to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in…
3 months ago benzinga.com
Why Is GH Research Stock Trading Higher on Thursday?
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved…
3 months ago proactiveinvestors.com
CleanSpark shares surge after company secures $6.6B data center lease agreement
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
3 months ago proactiveinvestors.com
Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
3 months ago proactiveinvestors.com
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that…
-
5 months ago benzinga.com
GH Research Announces Publication Of Full Results From Its Phase 2a Trial In Postpartum Depression
GH Research PLC (NASDAQ:GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World…
5 months ago globenewswire.com
GH Research Announces Publication of Phase 2a Postpartum Depression Results
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance…
5 months ago seekingalpha.com
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm
GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While…
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on GH Research, Lowers Price Target to $65
HC Wainwright & Co. analyst Patrick R. Trucchio maintains GH Research (NASDAQ:GHRS) with a Buy and lowers the price target from $70 to $65.
5 months ago benzinga.com
These Analysts Revise Their Forecasts On GH Research After Q1 Results
GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.
5 months ago benzinga.com
These Analysts Revise Their Forecasts On GH Research After Q1 Results
GH Research (NASDAQ:GHRS) reported a larger loss than expected in Q1. Analysts lowered price targets, stock fell 3.4%. CEO noted progress in GH001 program.
-
5 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $35
Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $25 to $35.
-
5 months ago benzinga.com
Citizens Maintains Market Outperform on GH Research, Lowers Price Target to $39
Citizens analyst Jason N. Butler maintains GH Research (NASDAQ:GHRS) with a Market Outperform and lowers the price target from $42 to $39.
-
5 months ago benzinga.com
GH Research Q1 EPS $(0.31) Misses $(0.28) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 63.16 percent decrease over losses of…
5 months ago globenewswire.com
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study…
-
5 months ago benzinga.com
'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive
Health officials explored restricting specific antidepressants among SSRI drugs-sources
-
6 months ago benzinga.com
GH Research Prices ~$117.5M Offering Of 6.528M Shares At $18/Share
GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced…
6 months ago globenewswire.com
GH Research Announces Pricing of $117.5 Million Underwritten Offering
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing…
6 months ago proactiveinvestors.com
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
6 months ago benzinga.com
Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday
Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI.
6 months ago globenewswire.com
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing…
6 months ago feeds.benzinga.com
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?
Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews
6 months ago benzinga.com
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?
Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews
6 months ago proactiveinvestors.com
Psychedelics stocks rise after Trump order expands research, access pathways
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...
6 months ago benzinga.com
Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $17 billion. Shares jump 20.2% to $493.01.
6 months ago defenseworld.net
Comparing Prenetics Global (NASDAQ:PRE) & GH Research (NASDAQ:GHRS)
Prenetics Global (NASDAQ: PRE - Get Free Report) and GH Research (NASDAQ: GHRS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two…
-
7 months ago benzinga.com
'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment
https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-treatment-for-veterans/
-
7 months ago benzinga.com
GH Research Announces Two-Peer Reviewed Publications From Its Phase 2B Clinical Program Of GH001 For Treatment-Resistant Depression
GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced…
7 months ago globenewswire.com
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing…
7 months ago seekingalpha.com
GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3
GH Research PLC remains well-capitalized with $280.7 million in cash, supporting its lead candidate GH001 for Treatment-Resistant Depression. GHRS's investment thesis centers on replicating strong…
-
8 months ago benzinga.com
Citizens Maintains Market Outperform on GH Research, Raises Price Target to $42
Citizens analyst Jason N. Butler maintains GH Research (NASDAQ:GHRS) with a Market Outperform and raises the price target from $39 to $42.
-
8 months ago benzinga.com
Needham Maintains Buy on GH Research, Raises Price Target to $32
Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $31 to $32.
-
8 months ago benzinga.com
GH Research Q4 EPS $(0.23) Beats $(0.28) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 17.56 percent. This is a 35.29 percent decrease over losses of $(0.17)…
-
8 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on GH Research, Raises Price Target to $70
HC Wainwright & Co. analyst Patrick R. Trucchio maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $35 to $70.
-
9 months ago benzinga.com
RBC Capital Maintains Outperform on GH Research, Raises Price Target to $40
RBC Capital analyst Brian Abrahams maintains GH Research (NASDAQ:GHRS) with a Outperform and raises the price target from $33 to $40.
-
10 months ago benzinga.com
Canaccord Genuity Maintains Buy on GH Research, Raises Price Target to $39
Canaccord Genuity analyst Sumant Kulkarni maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $35 to $39.
-
10 months ago benzinga.com
Needham Maintains Buy on GH Research, Raises Price Target to $29
Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $19 to $29.
10 months ago benzinga.com
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December